免疫检查点抑制剂联合治疗合并下腔静脉癌栓的肾细胞癌。
Immune Checkpoint Inhibitor Combination Therapy for Renal Cell Carcinomas With Concomitant Inferior Vena Cava Thrombi.
机构信息
Department of Urology, Tokyo Women's Medical University Hospital, Tokyo, Japan;
Department of Urology, Tokyo Women's Medical University Hospital, Tokyo, Japan.
出版信息
In Vivo. 2022 Mar-Apr;36(2):1030-1034. doi: 10.21873/invivo.12798.
Abstract
BACKGROUND/AIM: The efficacy of immune checkpoint inhibitor (ICI) combinations in treating inferior vena cava (IVC) tumour thrombi has not yet been reported. We aimed to evaluate the clinical efficacy of ICIs for patients with renal cell carcinoma (RCC) and a concomitant IVC tumour thrombus.
PATIENTS AND METHODS
Three men and two women with RCC and an IVC tumour thrombus were administered ICIs in 2020-2021. Three and two patients received nivolumab plus ipilimumab and pembrolizumab plus axitinib therapy, respectively.
RESULTS
All ICI-treated patients showed tumour shrinkage. The IVC thrombus level was downstaged in two patients. The mean reduction in maximum primary tumour diameter and IVC thrombus height was 34 and 33 mm, respectively.
CONCLUSION
Presurgical ICI therapy in three patients who underwent radical nephrectomy with thrombectomy resulted in a modified surgical strategy and approach and reduced surgical risk. Thus, ICIs may treat select cases of RCC with an IVC tumour thrombus effectively.
摘要
背景/目的：免疫检查点抑制剂（ICI）联合治疗下腔静脉（IVC）肿瘤血栓的疗效尚未见报道。我们旨在评估ICI 治疗合并 IVC 肿瘤血栓的肾细胞癌（RCC）患者的临床疗效。
患者和方法
2020 年至 2021 年期间，3 名男性和 2 名女性 RCC 合并 IVC 肿瘤血栓患者接受了 ICI 治疗。其中 3 名和 2 名患者分别接受了纳武利尤单抗联合伊匹单抗和帕博利珠单抗联合阿昔替尼治疗。
结果
所有接受 ICI 治疗的患者均显示肿瘤缩小。2 名患者的 IVC 血栓分级下降。最大原发肿瘤直径和 IVC 血栓高度的平均缩小分别为 34mm 和 33mm。
结论
对 3 例接受根治性肾切除术加血栓切除术的患者进行术前 ICI 治疗，改变了手术策略和方法，降低了手术风险。因此，ICI 可能对选择的 IVC 肿瘤血栓 RCC 病例有效。
相似文献
1
Immune Checkpoint Inhibitor Combination Therapy for Renal Cell Carcinomas With Concomitant Inferior Vena Cava Thrombi.免疫检查点抑制剂联合治疗合并下腔静脉癌栓的肾细胞癌。
In Vivo. 2022 Mar-Apr;36(2):1030-1034. doi: 10.21873/invivo.12798.
2
Bland thrombus association with tumour thrombus in renal cell carcinoma: analysis of surgical significance and role of inferior vena caval interruption.肾细胞癌中肿瘤栓子与无病变血栓的关系：分析手术意义及下腔静脉阻断的作用。
BJU Int. 2012 Dec;110(11 Pt B):E449-55. doi: 10.1111/j.1464-410X.2012.11128.x. Epub 2012 Apr 30.
3
Presurgical axitinib therapy increases fibrotic reactions within tumor thrombus in renal cell carcinoma with thrombus extending to the inferior vena cava.术前阿昔替尼治疗可增加肾癌合并瘤栓延伸至下腔静脉的肿瘤栓内纤维反应。
Int J Clin Oncol. 2018 Feb;23(1):134-141. doi: 10.1007/s10147-017-1169-z. Epub 2017 Jul 27.
4
Comparative analysis of dual immune checkpoint inhibitor combination therapy versus immune checkpoint inhibitor plus tyrosine kinase inhibitor combination therapy for renal cell carcinoma with inferior vena cava tumor thrombosis.对比分析双重免疫检查点抑制剂联合治疗与免疫检查点抑制剂联合酪氨酸激酶抑制剂治疗伴下腔静脉瘤栓的肾细胞癌。
Int J Clin Oncol. 2024 Oct;29(10):1538-1547. doi: 10.1007/s10147-024-02598-w. Epub 2024 Aug 7.
5
Laparoscopic Radical Nephrectomy and Inferior Vena Cava Thrombectomy in the Treatment of Renal Cell Carcinoma.腹腔镜根治性肾切除术和下腔静脉取栓术治疗肾细胞癌。
Eur Urol. 2015 Jul;68(1):115-22. doi: 10.1016/j.eururo.2014.12.011. Epub 2014 Dec 19.
6
Advanced Renal Cell Carcinoma With Inferior Vena Cava Thrombus Treated With a Combination of Preoperative Lenvatinib and Pembrolizumab.术前使用乐伐替尼和帕博利珠单抗联合治疗伴有下腔静脉血栓的晚期肾细胞癌。
Anticancer Res. 2024 Mar;44(3):1317-1321. doi: 10.21873/anticanres.16927.
7
Surgical strategy for treating renal cell carcinoma with thrombus extending into the inferior vena cava.治疗肾细胞癌伴血栓延伸至下腔静脉的手术策略。
J Vasc Surg. 2004 Apr;39(4):829-35. doi: 10.1016/j.jvs.2003.12.004.
8
[Outcome of Resection of Inferior Vena Cava Superior to the Renal Vein in Renal Cell Carcinoma with Vena Caval Tumor Thrombus].[肾细胞癌伴腔静脉瘤栓患者肾静脉上方下腔静脉切除术的结果]
Hinyokika Kiyo. 2016 Jun;62(6):287-94.
9
Clinical and radiographic predictors of the need for inferior vena cava resection during nephrectomy for patients with renal cell carcinoma and caval tumour thrombus.肾细胞癌合并腔静脉瘤栓患者肾切除术中下腔静脉切除必要性的临床及影像学预测因素
BJU Int. 2015 Sep;116(3):388-96. doi: 10.1111/bju.13005. Epub 2015 Mar 23.
10
Surgical management of renal cell carcinoma with inferior vena cava tumor thrombus.伴有下腔静脉瘤栓的肾细胞癌的外科治疗
Am J Surg. 2002 Mar;183(3):292-9. doi: 10.1016/s0002-9610(02)00782-1.
引用本文的文献
1
Neoadjuvant therapy demonstrates both safety and clinical feasibility for renal cell carcinoma patients with tumor thrombus.新辅助治疗对患有肿瘤血栓的肾细胞癌患者显示出安全性和临床可行性。
Discov Oncol. 2025 Aug 26;16(1):1630. doi: 10.1007/s12672-025-03489-w.
2
Two-Stage Tumor Resection for Locally Advanced Renal Cell Carcinoma With Level IV Tumor Thrombus and Pulmonary Embolism: A Case Report.两阶段肿瘤切除术治疗伴有IV级肿瘤血栓和肺栓塞的局部晚期肾细胞癌：病例报告
IJU Case Rep. 2025 Jun 16;8(4):382-385. doi: 10.1002/iju5.70045. eCollection 2025 Jul.
3
Impact of presurgical systemic therapy on perioperative outcomes of renal cell carcinoma with inferior vena cava tumor thrombus.术前全身治疗对伴有下腔静脉瘤栓的肾细胞癌围手术期结局的影响
Int J Clin Oncol. 2025 Mar;30(3):532-538. doi: 10.1007/s10147-024-02680-3. Epub 2024 Dec 12.
4
A case report of robot-assisted radical nephrectomy and inferior vena cava thrombectomy in a patient with renal cell carcinoma after pembrolizumab and axitinib combination therapy.帕博利珠单抗和阿昔替尼联合治疗后肾细胞癌患者行机器人辅助根治性肾切除术及下腔静脉血栓切除术的病例报告
Transl Cancer Res. 2024 Sep 30;13(9):5141-5148. doi: 10.21037/tcr-23-1547. Epub 2024 Sep 27.
5
Neoadjuvant toripalimab plus axitinib for clear cell renal cell carcinoma with inferior vena cava tumor thrombus: NEOTAX, a phase 2 study.特瑞普利单抗联合阿昔替尼新辅助治疗伴下腔静脉瘤栓的肾透明细胞癌：NEOTAX，一项 2 期研究。
Signal Transduct Target Ther. 2024 Oct 4;9(1):264. doi: 10.1038/s41392-024-01990-2.
6
Comparative analysis of dual immune checkpoint inhibitor combination therapy versus immune checkpoint inhibitor plus tyrosine kinase inhibitor combination therapy for renal cell carcinoma with inferior vena cava tumor thrombosis.对比分析双重免疫检查点抑制剂联合治疗与免疫检查点抑制剂联合酪氨酸激酶抑制剂治疗伴下腔静脉瘤栓的肾细胞癌。
Int J Clin Oncol. 2024 Oct;29(10):1538-1547. doi: 10.1007/s10147-024-02598-w. Epub 2024 Aug 7.
7
Systemic therapies and primary tumour downsizing in renal cell carcinoma: a real-world comparison of anti-angiogenic and immune checkpoint inhibition regimens.系统治疗和肾细胞癌原发肿瘤缩小：抗血管生成和免疫检查点抑制方案的真实世界比较。
World J Urol. 2024 Jul 24;42(1):442. doi: 10.1007/s00345-024-05133-8.
8
Management of Renal Cell Carcinoma With Supradiaphragmatic Inferior Vena Cava Thrombus Diagnosed During Acute COVID-19 Infection.急性COVID-19感染期间诊断出的伴有膈上腔静脉血栓形成的肾细胞癌的管理
Cureus. 2024 Mar 5;16(3):e55565. doi: 10.7759/cureus.55565. eCollection 2024 Mar.
9
A case of postoperative pancreatitis in patients with renal cell carcinoma with an inferior vena cava tumor thrombus treated by presurgical lenvatinib plus pembrolizumab.一例肾细胞癌伴下腔静脉瘤栓患者术前使用乐伐替尼联合帕博利珠单抗治疗后发生术后胰腺炎的病例。
Int Cancer Conf J. 2024 Feb 14;13(2):158-161. doi: 10.1007/s13691-024-00657-7. eCollection 2024 Apr.
10
Sarcomatoid renal cell carcinoma with an inferior vena cava tumor thrombus that was completely resected by robot-assisted laparoscopic radical nephrectomy after neoadjuvant therapy nivolumab plus ipilimumab: a case report.经新辅助治疗纳武单抗联合伊匹单抗后，通过机器人辅助腹腔镜根治性肾切除术完全切除伴有下腔静脉肿瘤血栓的肉瘤样肾细胞癌：一例报告
Int Cancer Conf J. 2023 Aug 19;13(1):6-10. doi: 10.1007/s13691-023-00627-5. eCollection 2024 Jan.
本文引用的文献
1
Updated European Association of Urology Guidelines on Renal Cell Carcinoma: Nivolumab plus Cabozantinib Joins Immune Checkpoint Inhibition Combination Therapies for Treatment-naïve Metastatic Clear-Cell Renal Cell Carcinoma.更新的欧洲泌尿外科学会肾癌指南：纳武利尤单抗联合卡博替尼加入免疫检查点抑制联合治疗用于治疗初治转移性透明细胞肾细胞癌。
Eur Urol. 2021 Mar;79(3):339-342. doi: 10.1016/j.eururo.2020.12.005. Epub 2020 Dec 24.
2
Presurgical Pazopanib Improves Surgical Outcomes for Renal Cell Carcinoma With High-level IVC Tumor Thrombosis.术前帕唑帕尼改善高水平 IVC 肿瘤血栓形成的肾细胞癌手术结果。
In Vivo. 2019 Nov-Dec;33(6):2013-2019. doi: 10.21873/invivo.11698.
3
Pembrolizumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma.派姆单抗联合阿昔替尼对比舒尼替尼用于晚期肾细胞癌。
N Engl J Med. 2019 Mar 21;380(12):1116-1127. doi: 10.1056/NEJMoa1816714. Epub 2019 Feb 16.
4
Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell Carcinoma.纳武利尤单抗联合伊匹木单抗与舒尼替尼治疗晚期肾细胞癌的比较
N Engl J Med. 2018 Apr 5;378(14):1277-1290. doi: 10.1056/NEJMoa1712126. Epub 2018 Mar 21.
5
Surgical Resection of Malignancies Invading Inferior Level I and II. Issues Still Need to Be Discussed.侵犯Ⅰ级和Ⅱ级下区恶性肿瘤的手术切除。仍需讨论的问题。
Anticancer Res. 2017 May;37(5):2523-2528. doi: 10.21873/anticanres.11594.
6
Limited benefit of targeted molecular therapy for inferior vena cava thrombus associated with renal cell carcinoma.靶向分子疗法对肾细胞癌伴下腔静脉血栓形成的疗效有限。
Int J Clin Oncol. 2017 Aug;22(4):767-773. doi: 10.1007/s10147-017-1119-9. Epub 2017 Apr 1.
7
Clinical and histopathological effects of presurgical treatment with sunitinib for renal cell carcinoma with inferior vena cava tumor thrombus at a single institution.单中心研究：舒尼替尼术前治疗对伴有下腔静脉瘤栓的肾细胞癌的临床及组织病理学影响
Anticancer Drugs. 2016 Nov;27(10):1038-43. doi: 10.1097/CAD.0000000000000422.
8
Neoadjuvant targeted molecular therapies in patients undergoing nephrectomy and inferior vena cava thrombectomy: is it useful?接受肾切除术和下腔静脉血栓切除术患者的新辅助靶向分子疗法：有用吗？
World J Urol. 2014 Feb;32(1):109-14. doi: 10.1007/s00345-013-1088-1. Epub 2013 Apr 27.
9
Presurgical treatment with sunitinib for renal cell carcinoma with a level III/IV vena cava tumour thrombus.舒尼替尼术前治疗伴 III/IV 级腔静脉瘤栓的肾细胞癌。
Anticancer Res. 2012 May;32(5):1729-35.
10
Duplicated vena cava with tumor thrombus from renal cancer: use of venogram for safer operative planning.肾癌合并肿瘤血栓的重复腔静脉：静脉造影术在更安全手术规划中的应用。
Urology. 2012 Apr;79(4):e57-8. doi: 10.1016/j.urology.2011.06.044. Epub 2011 Aug 20.
Zotero 插件